Beta Cat Pharmaceuticals is developing compounds which modulate beta catenin and are in the translational phase. These compounds target beta catenin, the end result of seminal mutations in the APC/WNT pathway, and modulate it by degrading it in the cytoplasm, and denying it access to the nucleus, where it is believed to be highly oncologic and drive cancer growth as a cancer stem cell pathway.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- betacatpharma.com
Beta Cat Pharmaceuticals Questions
Beta Cat Pharmaceuticals's website is betacatpharma.com
Beta Cat Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/beta-cat-pharmaceuticals
Beta Cat Pharmaceuticals's industry is
Biotechnology Research
Beta Cat Pharmaceuticals's top competitors are
Innovative Discovery Partners,
Stingray Therapeutics,
Iterion Therapeutics,
Tgen - Part Of City Of Hope,
Salarius Pharmaceuticals.
Beta Cat Pharmaceuticals's categories are Biotechnology Research
Beta Cat Pharmaceuticals's founding year is 2010
